Futura Medical to Get $4 Million Initial Payment on US Licensing Agreement
17 Julio 2023 - 1:48AM
Noticias Dow Jones
By Anthony O. Goriainoff
Futura Medical said Monday that it will receive an initial
upfront $4 million payment as part of the licensing agreement
reached with Haleon for the rights to exclusively commercialize its
erectile dysfunction treatment, MED3000.
The U.K. pharmaceutical developer focused on sexual health and
pain relief said potential commercial and performance-driven sales
milestone payments totaling between $5 million and $45 million are
payable over the course of several years.
It added that Haleon will be responsible for the future launch
as well as the continuing regulatory, development, marketing, and
commercialization of MED3000 in the U.S.
"MED3000 has previously been approved as the first pan-European
clinically proven topical treatment for ED available over the
counter and is now available in Belgium and the U.K." the company
said
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
July 17, 2023 02:33 ET (06:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De May 2023 a May 2024